Pacira Pharmaceuticals (PCRX) Price Target Cut to $32.00

Pacira Pharmaceuticals (NASDAQ:PCRX) had its price objective decreased by BMO Capital Markets from $41.00 to $32.00 in a report issued on Thursday. BMO Capital Markets currently has a market perform rating on the stock.

Several other research firms have also recently commented on PCRX. Jefferies Group decreased their price target on shares of Pacira Pharmaceuticals to $52.00 and set a buy rating for the company in a report on Thursday, November 9th. ValuEngine upgraded shares of Pacira Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, January 10th. Canaccord Genuity set a $42.00 price target on shares of Pacira Pharmaceuticals and gave the stock a hold rating in a report on Wednesday, November 29th. Piper Jaffray Companies reiterated a buy rating and issued a $55.00 target price on shares of Pacira Pharmaceuticals in a research note on Friday, October 27th. Finally, Wedbush reiterated an outperform rating and issued a $87.00 target price on shares of Pacira Pharmaceuticals in a research note on Wednesday, October 25th. Four investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $46.53.

Shares of Pacira Pharmaceuticals (PCRX) opened at $30.15 on Thursday. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03. The company has a market cap of $1,220.00, a P/E ratio of -23.02 and a beta of 1.88. Pacira Pharmaceuticals has a fifty-two week low of $29.35 and a fifty-two week high of $58.95.

In other news, CEO David M. Stack sold 28,885 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $40.19, for a total value of $1,160,888.15. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 6.60% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. MetLife Investment Advisors LLC bought a new position in shares of Pacira Pharmaceuticals in the fourth quarter valued at approximately $845,000. Redmile Group LLC bought a new position in shares of Pacira Pharmaceuticals in the fourth quarter valued at approximately $237,000. Element Capital Management LLC bought a new position in shares of Pacira Pharmaceuticals in the fourth quarter valued at approximately $6,144,000. Macquarie Group Ltd. raised its position in shares of Pacira Pharmaceuticals by 9.7% in the fourth quarter. Macquarie Group Ltd. now owns 1,266,414 shares of the company’s stock valued at $57,812,000 after purchasing an additional 111,869 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of Pacira Pharmaceuticals in the fourth quarter valued at approximately $501,000.

COPYRIGHT VIOLATION NOTICE: “Pacira Pharmaceuticals (PCRX) Price Target Cut to $32.00” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/02/19/pacira-pharmaceuticals-pcrx-price-target-cut-to-32-00-2.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply